ClinicalTrials.Veeva

Menu

Vitamin D Regulation of Gut Specific B Cells and Antibodies Targeting Gut Bacteria in Inflammatory Bowel Disease

Stanford University logo

Stanford University

Status and phase

Completed
Phase 1

Conditions

Ulcerative Colitis
Inflammatory Bowel Diseases
Crohn Disease

Treatments

Drug: Vitamin D

Study type

Interventional

Funder types

Other

Identifiers

NCT04828031
IRB-60958

Details and patient eligibility

About

Specific Aim 1: Characterize the effects of vitamin D treatment on expression of α4β7 on B cells in patients with inflammatory bowel disease (IBD).

Specific Aim 2: Determine the effects of vitamin D treatment on fecal immunoglobulins, percentage of Ig-coated gut bacteria, gut microbiome composition (global and bound by immunoglobulins) in patients with IBD and the association of these parameters with change in α4β7+ B cells .

Specific Aim 3: Compare BCR repertoire (BCR clonotypes, immunoglobulin heavy chain gene (IGHV), and isotype usage) between α4β7+ and α4β7- B cells in patients with IBD and identify α4β7+ BCR clonotypes associated with Ig-bound gut bacteria .

Enrollment

48 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients (18 years or older) with inflammatory bowel disease (ulcerative colitis or Crohn's disease)
  • Low serum vitamin D (25(OH)D ≤ 25 ng/mL
  • Not currently on high dose vitamin D supplementation
  • No prior bowel resections
  • No antibiotic use in past 3 months.

Exclusion criteria

  • Patients less than 18 years old
  • No diagnosis of IBD
  • Serum 25(OH)D > 25 ng/mL
  • Patients already on vitamin D supplementation
  • Prior history of bowel surgery (colectomy or small bowel resections)
  • Recent antibiotic use in past 3 months
  • Renal Dysfunction
  • History of Hypercalcemia
  • History of HIV
  • History of IgA deficiency
  • History of Common Variable Immunodeficiency (CVID)
  • Active C. diff infection

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

48 participants in 1 patient group

Vitamin D 50,000 IU PO every week
Experimental group
Description:
Vitamin D 50,000 IU PO every week for 12 weeks
Treatment:
Drug: Vitamin D

Trial contacts and locations

1

Loading...

Central trial contact

John Mark Gubatan, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems